GlassScriptPhysician profile
Christopher A Smith
NPI 1679675995
$622,425.63
in general payments reported to CMS, 2019-2025
41 companies · $112K in 2025
The $112K reported for 2025 was more than what 97% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $35K · 2021: $51K · 2022: $104K · 2023: $108K · 2024: $125K · 2025: $112K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $284K · Travel and Lodging: $23K · Consulting Fee: $20K · Food and Beverage: $18K · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $283,747.50 |
| Travel and Lodging | $22,747.48 |
| Consulting Fee | $20,318.74 |
| Food and Beverage | $17,811.12 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299,701.40 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $135,191.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $81,494.80 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $37,024.08 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $20,284.90 | 2019-2025 | Joenja, Ruconest |
| Amgen INC. | $12,142.54 | 2021-2025 | Tezspire, Actimmune |
| Genentech USA, INC. | $8,880.23 | 2019-2025 | Xolair |
| Genentech, INC. | $6,792.33 | 2019-2022 | |
| Shire North American Group INC | $5,603.82 | 2019 | |
| Merck Sharp & Dohme LLC | $3,271.61 | 2019-2023 | |
| Grifols USA, LLC | $3,167.75 | 2019-2025 | Xembify, Gamunex-C, Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $1,939.18 | 2019-2025 | |
| Pfizer INC. | $1,355.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,245.16 | 2020-2025 | Cuvitru, Hyqvia, Eohilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $658.75 | 2019-2024 | Spiriva Respimat, Stiolto Respimat |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $543.05 | 2019-2025 | |
| Csl Behring | $497.83 | 2019-2025 | Hizentra, Haegarda |
| Biocryst US Sales Co., LLC | $432.22 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $405.63 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $326.72 | 2024-2025 | Dupixent |
| Octapharma USA, INC. | $295.27 | 2022-2025 | Cutaquig, Panzyga |
| Alk-Abello, INC | $196.72 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Abbvie INC. | $183.98 | 2022-2025 | Rinvoq |
| Blueprint Medicines Corporation | $175.26 | 2023-2025 | Ayvakit |
| Aimmune Therapeutics, INC. | $148.74 | 2020-2021 | |
| Adma Biomanufacturing LLC | $129.40 | 2022-2025 | |
| Kaleo, INC. | $67.50 | 2020-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $64.33 | 2025 | Neffy |
| Lilly USA, LLC | $50.82 | 2025 | Ebglyss |
| Horizon Therapeutics Plc | $45.10 | 2021-2022 | |
| Emd Serono, INC. | $26.34 | 2025 | |
| Gc Biopharma USA, INC. | $21.37 | 2024 | Alyglo |
| Incyte Corporation | $17.64 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Galderma Laboratories, L.P. | $14.93 | 2025 | Nemluvio |
| Bio Products Laboratory USA, INC. | $14.22 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.